Developmental Research Program

项目摘要/摘要(DRP) 乳腺癌经常存在特殊类型的同源重组(HR)DNA修复缺陷(HRD) 和/或特定的遗传不稳定模式，即染色体不稳定(CIN)和APOBEC突变。 这些改变存在于相当大比例的乳腺癌中，并且在转移性乳腺癌中更为丰富。 疾病。可靠地识别这些患者并确定这些患者的最佳治疗方案的生物标志物是 这是非常需要的。发展研究计划(DRP)将在培养翻译能力方面发挥重要作用 专注于乳腺癌的研究，特别是针对特定DNA修复模式的研究 缺陷和/或遗传不稳定性及其分子基础。我们将使用DRP资金并辅之以强大的 机构资金承诺支持新的和已有的调查员的创新项目，这些项目是 对于诊断和治疗这一大类乳腺癌的新想法的产生至关重要。我们的 目标是建立机制，为重要的新方向快速供资，以加快实现 我们孢子的翻译研究目标。我们确定了一个可信的、有前途的发展组合 研究项目，一旦该计划建立，这些项目将竞争支持。我们将请求飞行员 更大的MSKCC内临床和基础研究人员提出的具有翻译潜力的项目建议 社区，包括洛克菲勒大学、纽约长老会医院和威尔·康奈尔医学院 康奈尔大学的。然后，我们将经过严格的同行审查，选择最有希望的新项目进行支持 由领导委员会、内部咨询委员会和患者倡导者。外部人士的观点 评审员将根据需要进行征集。试点项目将获得为期1年的资金，但调查人员可申请 第二年通过同样的竞争过程获得额外资金。每年的咨询和领导 委员会成员将开会审查每个研究项目、核心项目、职业提升项目和 发展试点项目。委员会成员将被要求评估是否有任何发展项目 有足够的进展，并显示出足够的翻译潜力，以至于超过了一个完整的孢子 研究项目。然后，委员会成员将投票并决定是否应该 被推进到完全项目状态。如果是这样的话，预算将进行适当的调整，并与 NCI的TRP。

Project Abstract/ Summary (DRP) Breast cancers frequently harbor specific patterns of homologous recombination (HR) DNA repair defects (HRD) and/or specific patterns of genetic instability, namely chromosomal instability (CIN) and APOBEC mutagenesis. These alterations are present in a substantial proportion of breast cancers and they are enriched in metastatic disease. Biomarkers to identify these patients reliably and to define the optimal treatments for these patients are sorely needed. The Developmental Research Program (DRP) will play an important role in fostering translational research endeavors focusing on breast cancer, in particular research addressing specific patterns of DNA repair defects and/or genetic instability and their molecular basis. We will use DRP funding supplemented by a strong commitment of institutional funds to support innovative projects by new and established investigators, which are critical to the generation of new ideas in the diagnosis and treatment of this large subset of breast cancers. Our goal is to establish mechanisms for rapid funding of important new directions to accelerate progress towards the translational research goals of our SPORE. We identified a credible portfolio of promising developmental research projects, which will be competing for support once the program is established. We will request pilot project proposals with translational potential from clinical and basic investigators within the larger MSKCC community, including Rockefeller University, New York-Presbyterian Hospital and Weill Cornell Medical College of Cornell University. We will then select the most promising new projects for support after rigorous peer review by the Leadership Committee, the Internal Advisory Board and the Patient Advocates. The opinion of external reviewers will be solicited as needed. Pilot projects will be funded for 1 year, but investigators may apply for additional funding through this same competitive process the next year. Every year the Advisory and Leadership Committee members will meet to review each research project, core, career enhancement project and developmental pilot project. Committee members will be asked to assess whether any developmental project has progressed sufficiently and shown enough translational potential, so as to eclipse one of the full SPORE Research Projects. The committee members will then vote and decide whether any developmental project should be advanced to full project status. If so, the budgets will be appropriately adjusted and sent for approval with the TRP of the NCI.